{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:47:59Z","timestamp":1782445679120,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostatic artery embolization (PAE) is a safe and effective minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), including in patients with large prostates, who are poor surgical candidates or wish to avoid the morbidity of conventional surgery or transurethral interventions. As PAE becomes more widely adopted for BPH-related LUTS, objective measures of assessing treatment response are needed beyond symptom-based tools such as the International Prostate Symptom Score (IPSS) and Quality-of-Life (QoL) index. Imaging biomarkers complement these subjective endpoints by quantifying structural, functional, ischemic, and microstructural changes within the prostate before and after embolization. This review summarizes the principal imaging modalities used for biomarker assessment in PAE, with emphasis on ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and examines the current literature on imaging biomarkers of treatment response. Volumetric biomarkers, including whole prostate volume, central gland volume, and zonal volumetry index, provide quantitative assessment of gland reduction and may help predict clinical improvement, with zonal parameters showing stronger associations with symptomatic outcomes than whole-gland measurements alone. Functional biomarkers such as postvoid residual volume offer objective evaluation of bladder emptying alongside volumetric assessment, whereas ischemia-based biomarkers derived from contrast-enhanced MRI directly reflect embolization-induced devascularization. Diffusion-weighted imaging and apparent diffusion coefficient mapping provide additional information regarding post-embolization tissue remodeling, with b-value selection influencing early infarct detection. Emerging tools, including ultrasound elastography, radiomics, and artificial intelligence-assisted image analysis, may further refine patient selection, standardize response assessment, and improve predictive modeling, though prospective PAE-specific validation remains needed. Imaging biomarkers provide a more objective framework for evaluating PAE treatment response, with the potential to standardize outcome reporting, facilitate earlier identification of treatment success or failure, and guide biomarker-driven clinical decision-making. Prospective validation in larger PAE-specific cohorts remains essential before broader clinical adoption.<\/jats:p>","DOI":"10.1007\/s00261-026-05628-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:15:20Z","timestamp":1782443720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies"],"prefix":"10.1007","author":[{"given":"Gavin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umairullah","family":"Lodhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina S.","family":"Makary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"5628_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1148\/rg.2021200144","volume":"41","author":"US Dias Jr","year":"2021","unstructured":"Dias Jr US, De Moura MRL, Viana PCC, et al (2021) Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications. RadioGraphics 41:1509\u20131530. https:\/\/doi.org\/10.1148\/rg.2021200144","journal-title":"RadioGraphics"},{"key":"5628_CR2","unstructured":"Ng M, Leslie SW, Baradhi KM (2026) Benign Prostatic Hyperplasia. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"5628_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jvir.2019.02.013","volume":"30","author":"JP McWilliams","year":"2019","unstructured":"McWilliams JP, Bilhim TA, Carnevale FC, et al (2019) Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Soci\u00e9t\u00e9 Fran\u00e7aise de Radiologie, and the British Society of Interventional Radiology. J Vasc Interv Radiol 30:627\u2013637.e1. https:\/\/doi.org\/10.1016\/j.jvir.2019.02.013","journal-title":"J Vasc Interv Radiol"},{"key":"5628_CR4","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1007\/s00330-015-4177-2","volume":"26","author":"Y-T Lin","year":"2016","unstructured":"Lin Y-T, Amouyal G, Correas J-M, et al (2016) Can prostatic arterial embolisation (PAE) reduce the volume of the peripheral zone? MRI evaluation of zonal anatomy and infarction after PAE. Eur Radiol 26:3466\u20133473. https:\/\/doi.org\/10.1007\/s00330-015-4177-2","journal-title":"Eur Radiol"},{"key":"5628_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00261-024-04650-9","volume":"50","author":"J-L Lin","year":"2024","unstructured":"Lin J-L, Luo J-W, Fang Z (2024) Analysis of the efficacy of Prostatic Artery Embolization in the treatment of Benign Prostatic Hyperplasia. Abdom Radiol 50:1689\u20131698. https:\/\/doi.org\/10.1007\/s00261-024-04650-9","journal-title":"Abdom Radiol"},{"key":"5628_CR6","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.3390\/jcm10215139","volume":"10","author":"SG Naidu","year":"2021","unstructured":"Naidu SG, Narayanan H, Saini G, et al (2021) Prostate Artery Embolization\u2014Review of Indications, Patient Selection, Techniques and Results. J Clin Med 10:5139. https:\/\/doi.org\/10.3390\/jcm10215139","journal-title":"J Clin Med"},{"key":"5628_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00270-016-1518-8","volume":"40","author":"AM De Assis","year":"2017","unstructured":"De Assis AM, Maciel MS, Moreira AM, et al (2017) Prostate Zonal Volumetry as a Predictor of Clinical Outcomes for Prostate Artery Embolization. Cardiovasc Intervent Radiol 40:245\u2013251. https:\/\/doi.org\/10.1007\/s00270-016-1518-8","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5628_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jvir.2020.03.003","volume":"31","author":"AB Uflacker","year":"2020","unstructured":"Uflacker AB, Haskal ZJ, Baerlocher MO, et al (2020) Society of Interventional Radiology Research Reporting Standards for Prostatic Artery Embolization. J Vasc Interv Radiol 31:891\u2013898.e1. https:\/\/doi.org\/10.1016\/j.jvir.2020.03.003","journal-title":"J Vasc Interv Radiol"},{"key":"5628_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jvir.2018.02.019","volume":"29","author":"E Nzekwu","year":"2018","unstructured":"Nzekwu E, Mirakhur A, Lee A, Bakshi D (2018) Intra-Arterial and Intravenous Contrast-Enhanced Ultrasonography in Prostate Artery Embolization: A Case Series. J Vasc Interv Radiol 29:1399\u20131402. https:\/\/doi.org\/10.1016\/j.jvir.2018.02.019","journal-title":"J Vasc Interv Radiol"},{"key":"5628_CR10","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1007\/s00270-020-02518-1","volume":"43","author":"M Barat","year":"2020","unstructured":"Barat M, Boeken T, Moussa N, et al (2020) Contrast-Enhanced Ultrasonography for the Early Evaluation of Prostate Artery Embolization. Cardiovasc Intervent Radiol 43:1498\u20131504. https:\/\/doi.org\/10.1007\/s00270-020-02518-1","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5628_CR11","doi-asserted-by":"publisher","first-page":"e220096","DOI":"10.1148\/rg.220096","volume":"43","author":"EA Han","year":"2023","unstructured":"Han EA, Nandalur KR, Morgan MA, et al (2023) MRI of Benign Prostatic Hyperplasia: Important Pre- and Posttherapeutic Considerations. RadioGraphics 43:e220096. https:\/\/doi.org\/10.1148\/rg.220096","journal-title":"RadioGraphics"},{"key":"5628_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.crad.2016.05.003","volume":"71","author":"N Kisilevzky","year":"2016","unstructured":"Kisilevzky N, Faintuch S (2016) MRI assessment of prostatic ischaemia: best predictor of clinical success after prostatic artery embolisation for benign prostatic hyperplasia. Clin Radiol 71:876\u2013882. https:\/\/doi.org\/10.1016\/j.crad.2016.05.003","journal-title":"Clin Radiol"},{"key":"5628_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s42155-025-00562-x","volume":"8","author":"S Sammoud","year":"2025","unstructured":"Sammoud S, De Oliviera F, Kammoun T, et al (2025) Predicting early clinical success of prostate artery embolization using MRI perfusion in benign prostatic hyperplasia. CVIR Endovasc 8:46. https:\/\/doi.org\/10.1186\/s42155-025-00562-x","journal-title":"CVIR Endovasc"},{"key":"5628_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11547-018-0904-5","volume":"123","author":"H Zhang","year":"2018","unstructured":"Zhang H, Shen Y, Pan J, et al (2018) MRI features after prostatic artery embolization for the treatment of medium- and large-volume benign hyperplasia. Radiol Med (Torino) 123:727\u2013734. https:\/\/doi.org\/10.1007\/s11547-018-0904-5","journal-title":"Radiol Med (Torino)"},{"key":"5628_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/pros.24457","volume":"83","author":"KR Nandalur","year":"2023","unstructured":"Nandalur KR, Walker D, Ye H, et al (2023) Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis. The Prostate 83:259\u2013267. https:\/\/doi.org\/10.1002\/pros.24457","journal-title":"The Prostate"},{"key":"5628_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/diagnostics12030585","volume":"12","author":"VF Schmidt","year":"2022","unstructured":"Schmidt VF, Schirren M, Heimer MM, et al (2022) Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization. Diagnostics 12:585. https:\/\/doi.org\/10.3390\/diagnostics12030585","journal-title":"Diagnostics"},{"key":"5628_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00261-018-1757-z","volume":"44","author":"R Ali","year":"2019","unstructured":"Ali R, Gabr A, Mouli SK, et al (2019) MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study. Abdom Radiol 44:713\u2013722. https:\/\/doi.org\/10.1007\/s00261-018-1757-z","journal-title":"Abdom Radiol"},{"key":"5628_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.21037\/tau-20-437","volume":"9","author":"F Sun","year":"2020","unstructured":"Sun F, Lucas-Cava V, S\u00e1nchez-Margallo FM (2020) Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review. Transl Androl Urol 9:1754\u20131768. https:\/\/doi.org\/10.21037\/tau-20-437","journal-title":"Transl Androl Urol"},{"key":"5628_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1148\/radiol.2016152292","volume":"281","author":"T Bilhim","year":"2016","unstructured":"Bilhim T, Pisco J, Pereira JA, et al (2016) Predictors of Clinical Outcome after Prostate Artery Embolization with Spherical and Nonspherical Polyvinyl Alcohol Particles in Patients with Benign Prostatic Hyperplasia. Radiology 281:289\u2013300. https:\/\/doi.org\/10.1148\/radiol.2016152292","journal-title":"Radiology"},{"key":"5628_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2214\/AJR.13.11692","volume":"203","author":"NE Frenk","year":"2014","unstructured":"Frenk NE, Baroni RH, Carnevale FC, et al (2014) MRI findings after prostatic artery embolization for treatment of benign hyperplasia. AJR Am J Roentgenol 203:813\u2013821. https:\/\/doi.org\/10.2214\/AJR.13.11692","journal-title":"AJR Am J Roentgenol"},{"key":"5628_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s00270-025-04254-w","volume":"49","author":"C Von Stempel","year":"2025","unstructured":"Von Stempel C, Tzelves L, Khangura S, et al (2025) Three-Month Magnetic Resonance Imaging Post-Prostate Artery Embolization Predicts 1-Year Clinical Outcomes. Cardiovasc Intervent Radiol 49:370\u2013379. https:\/\/doi.org\/10.1007\/s00270-025-04254-w","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5628_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00261-023-04131-5","volume":"49","author":"R Wang","year":"2023","unstructured":"Wang R, Lin F, Ruan D, et al (2023) A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization. Abdom Radiol 49:927\u2013938. https:\/\/doi.org\/10.1007\/s00261-023-04131-5","journal-title":"Abdom Radiol"},{"key":"5628_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00270-019-02220-x","volume":"42","author":"AM De Assis","year":"2019","unstructured":"De Assis AM, Moreira AM, Carnevale FC, et al (2019) Effects of Prostatic Artery Embolization on the Dynamic Component of Benign Prostate Hyperplasia as Assessed by Ultrasound Elastography: A Pilot Series. Cardiovasc Intervent Radiol 42:1001\u20131007. https:\/\/doi.org\/10.1007\/s00270-019-02220-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5628_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jvir.2021.07.018","volume":"32","author":"AM De Assis","year":"2021","unstructured":"De Assis AM, Moreira AM, Carnevale FC, et al (2021) Role of Ultrasound Elastography in Patient Selection for Prostatic Artery Embolization. J Vasc Interv Radiol 32:1410\u20131416. https:\/\/doi.org\/10.1016\/j.jvir.2021.07.018","journal-title":"J Vasc Interv Radiol"},{"key":"5628_CR25","doi-asserted-by":"publisher","first-page":"20210539","DOI":"10.1259\/bjr.20210539","volume":"95","author":"H Cho","year":"2022","unstructured":"Cho H, Kim CK, Park H (2022) Overview of radiomics in prostate imaging and future directions. Br J Radiol 95:20210539. https:\/\/doi.org\/10.1259\/bjr.20210539","journal-title":"Br J Radiol"},{"key":"5628_CR26","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.3390\/ijms22189971","volume":"22","author":"M Ferro","year":"2021","unstructured":"Ferro M, De Cobelli O, Vartolomei MD, et al (2021) Prostate Cancer Radiogenomics\u2014From Imaging to Molecular Characterization. Int J Mol Sci 22:9971. https:\/\/doi.org\/10.3390\/ijms22189971","journal-title":"Int J Mol Sci"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05628-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05628-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:15:27Z","timestamp":1782443727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05628-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":26,"alternative-id":["5628"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05628-5","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.C.H. is a consultant for Merit Medical and Varian. None of the other authors have identified a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}